PURPOSE: The identification of genes and pathways that are affected by estrogenization may shed light on the mechanisms of estrogen action. Here, we describe the expression pattern of a novel estrogen-induced gene, EIG121, in distinct types of endometrial cancer. EXPERIMENTAL DESIGN: EIG121 was identified by cDNA microarray analysis of endometrial RNA from women receiving either placebo or estrogen replacement therapy. The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples. A polyclonal antibody was used to detect EIG121 protein by immunohistochemistry. RESULTS: In postmenopausal endometrium, estrogen replacement therapy with Premarin and synthetic estrogen sulfate conjugates induced the expression of EIG121 2- and 3-fold, respectively. In premenopausal endometrium, the expression of EIG121 was higher in the estrogen-dominated proliferative phase than the secretory phase. In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors). Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage. Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors. In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium. CONCLUSIONS: Our results suggest that EIG121 is a good endometrial biomarker associated with a hyperestrogenic state and estrogen-related type I endometrial adenocarcinoma.
RCT Entities:
PURPOSE: The identification of genes and pathways that are affected by estrogenization may shed light on the mechanisms of estrogen action. Here, we describe the expression pattern of a novel estrogen-induced gene, EIG121, in distinct types of endometrial cancer. EXPERIMENTAL DESIGN:EIG121 was identified by cDNA microarray analysis of endometrial RNA from women receiving either placebo or estrogen replacement therapy. The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples. A polyclonal antibody was used to detect EIG121 protein by immunohistochemistry. RESULTS: In postmenopausal endometrium, estrogen replacement therapy with Premarin and synthetic estrogen sulfate conjugates induced the expression of EIG121 2- and 3-fold, respectively. In premenopausal endometrium, the expression of EIG121 was higher in the estrogen-dominated proliferative phase than the secretory phase. In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors). Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage. Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors. In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium. CONCLUSIONS: Our results suggest that EIG121 is a good endometrial biomarker associated with a hyperestrogenic state and estrogen-related type I endometrial adenocarcinoma.
Authors: Nancy H Nabilsi; Russell R Broaddus; Adrienne S McCampbell; Karen H Lu; Henry T Lynch; Lee-May Chen; David S Loose Journal: J Endocrinol Date: 2010-08-26 Impact factor: 4.286
Authors: Jeannelyn S Estrella; Ly T Ma; Denái R Milton; James C Yao; Huamin Wang; Asif Rashid; Russell R Broaddus Journal: Pancreas Date: 2014-10 Impact factor: 3.327
Authors: Shannon N Westin; Russell R Broaddus; Lei Deng; Adrienne McCampbell; Karen H Lu; Robin A Lacour; Michael R Milam; Diana L Urbauer; Peter Mueller; James H Pickar; David S Loose Journal: Cancer Biol Ther Date: 2009-11-05 Impact factor: 4.742
Authors: Karen H Lu; David S Loose; Melinda S Yates; Graciela M Nogueras-Gonzalez; Mark F Munsell; Lee-May Chen; Henry Lynch; Terri Cornelison; Stephanie Boyd-Rogers; Mary Rubin; Molly S Daniels; Peggy Conrad; Andrea Milbourne; David M Gershenson; Russell R Broaddus Journal: Cancer Prev Res (Phila) Date: 2013-05-02
Authors: Rebecca L Stone; Alpa M Nick; Iain A McNeish; Frances Balkwill; Hee Dong Han; Justin Bottsford-Miller; Rajesha Rupairmoole; Guillermo N Armaiz-Pena; Chad V Pecot; Jermaine Coward; Michael T Deavers; Hernan G Vasquez; Diana Urbauer; Charles N Landen; Wei Hu; Hannah Gershenson; Koji Matsuo; Mian M K Shahzad; Erin R King; Ibrahim Tekedereli; Bulent Ozpolat; Edward H Ahn; Virginia K Bond; Rui Wang; Angela F Drew; Francisca Gushiken; Donald Lamkin; Katherine Collins; Koen DeGeest; Susan K Lutgendorf; Wah Chiu; Gabriel Lopez-Berestein; Vahid Afshar-Kharghan; Anil K Sood Journal: N Engl J Med Date: 2012-02-16 Impact factor: 91.245
Authors: Joseph A Dottino; Qian Zhang; David S Loose; Bryan Fellman; Brenda D Melendez; Mikayla S Borthwick; Laurie J McKenzie; Ying Yuan; Richard K Yang; Russell R Broaddus; Karen H Lu; Pamela T Soliman; Melinda S Yates Journal: Am J Obstet Gynecol Date: 2020-08-21 Impact factor: 8.661